Login to Your Account

Durect, Endo Form Sufentanil Patch Deal Worth Up To $45M

By Karen Pihl-Carey

Tuesday, March 15, 2005
Durect Corp. formed a commercialization agreement worth up to $45 million in up-front and milestone payments for its transdermal patch pain product with Endo Pharmaceuticals Holdings Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription